IBA Renews Exclusive Four-Year Radiopharmaceuticals Contract in Andalusia, Spain

Louvain-la-Neuve, December 23, 2010 – IBA global developer of next generation radiopharmaceuticals used in molecular imaging, announced today it has renewed its exclusive four-year radiopharmaceuticals contract with Servicio Andaluz de Salud in Andalusia, Spain. Under the terms of the agreement, IBA will supply all radiopharmaceuticals for the 12 nuclear medicine departments located in the public hospitals in Andalusia, beginning in mid-January 2011. This includes both Positron Emission Tomography (PET) and Single Photon Emission Computed Tomography (SPECT) radiopharmaceuticals from IBA’s portfolio.

The new contract is valued at 33,775,555 Euros over a period of four years. Its renewal is a central element of IBA’s business development in Spain, where Andalusia represents approximately a fifth of the Spanish radiopharmaceuticals market. The contract is also recognition of IBA’s manufacturing and distribution expertise, and the company’s ability to deliver high-quality and reliable radiopharmaceuticals through its PET network, the largest in Europe.

“We are pleased to renew and expand our relationship with Servicio Andaluz de Salud, which will provide imaging specialists across Andalusia with access to our growing portfolio of radiopharmaceuticals,” said Pierre Mottet, Chief Executive Officer of IBA. “Through this contract, we will further support the development of personalized medicine in Spain, and the earlier and more accurate detection of major diseases.”

IBA has the only global PET network in the industry, with 57 PET facilities, and the most modern SPECT facility. These enable the company to manage direct distribution in the USA, Europe and India and deliver its products to 60 countries.

About IBA

IBA is global developer, manufacturer and distributor of radiopharmaceutical products and supporting services used in molecular imaging. With radiopharmaceutical innovation capabilities that address indications in oncology, cardiology and neurology, in PET, SPECT and therapy, IBA has engineered a strong and unique product portfolio and pipeline of diagnostic tracers aimed at contributing to the development of the global trend towards personalized medicine and making molecular imaging a major discipline in healthcare. The company also provides educational, technical and marketing support to medical specialists worldwide to help better respond to unmet patient needs. IBA was awarded Frost & Sullivan’s European Radiopharmaceuticals Technology Leadership of the Year prize in 2010.

IBA develops and markets leading edge technologies, pharmaceuticals and tailor-made solutions for healthcare with a focus on cancer diagnosis and therapy. Leveraging on its scientific expertise, IBA is also active in the field of industrial sterilization and ionization.

Listed on the pan-European stock exchange EURONEXT, IBA is included in the BelMid Index. (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB).

Please visit www.iba-worldwide.com for more information about IBA

Contact

IBA Jean-Marc Bothy Chief Financial Officer Tel.: +32 10 47 58 90 Jean-Marc.Bothy@iba-group.com